American Society of Hirudotherapy

Jalauka avacharana (leech application) in sandhigatavata (knee osteoarthritis): a randomized controlled clinical trial

Karandikar S, Kulkarni P, Kale H, Mehta CR (2018) · AYU (An International Quarterly Journal of Research in Ayurveda) · n=60

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Karandikar S 201860
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized controlled trial (Pune, India)
Sample size (n)
60
Intervention
Three sessions of jalaukavacharana (leech application) using Hirudinaria granulosa, 15 days apart, periarticular knee
Comparator
Janu basti (Ayurvedic oil pooling therapy) for 7 days plus oral guggulu tablets for 30 days
Primary endpoint
WOMAC composite at day 45
Primary result
WOMAC composite improvement 39% in leech vs 24% in janu basti at day 45 (p=0.02)
Effect size (Cohen's d)
0.58
Follow-up duration
60 days

Key Findings

  • First RCT using Hirudinaria granulosa (Indian medicinal leech) rather than Hirudo medicinalis
  • Comparator was an active Ayurvedic intervention rather than conventional NSAID — applicable to Ayurveda-practice contexts
  • Effect emerged at day 15 and grew through day 45
  • Subjective stiffness improved more than objective range-of-motion measurements
  • No serious adverse events in either arm

Limitations

  • Open-label
  • Single center, Ayurveda institute — non-Ayurveda-favorable patients excluded
  • Different species (H. granulosa) — comparability to European H. medicinalis trials uncertain
  • WOMAC scoring not validated in Marathi/Hindi for this population
  • Short follow-up (60 days)

Clinical Implications

Karandikar 2018 extends the evidence base to Hirudinaria granulosa (Indian medicinal leech), a different species from the European Hirudo medicinalis used in all FDA-cleared US practice. For US clinicians, this trial is mostly of taxonomic interest — H. granulosa is not FDA-cleared and is not commercially available in the US. However, the demonstration of efficacy across leech species supports the hypothesis that the underlying salivary-compound mechanism is conserved.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.